Articles related to KIDNEY CANCER/RCC

Discover how SABR is setting a new standard in the treatment of inoperable renal cell carcinoma, offering exceptional cancer control with minimal side effects.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

Discover a holistic perspective on advanced bladder and renal cell cancers management, encompassing everything from pathogenesis to adverse event mitigation. Let’s dive into the “Advanced Bladder and Renal Cell Cancers Management” webcast, released on April 30, 2023, offering valuable 1.00 ANCC contact hour, inclusive of 0.75 pharmacology hours. Presented by expert Mary W. Dunn, MSN, RN, OCN, NP-C from the University of North Carolina, this program targets oncology nurses, nurse navigators, advanced nursing providers, and nurses from other cancer-related subspecialties. It remains available until April 30, 2024, leaving ample time to gain this crucial knowledge. Primarily, this webcast zeroes in on bladder cancer (BC), a malignancy notorious for its high mortality rate, and renal cell carcinoma (RCC), a top-10 common cancer. Unfortunately, BC’s 5% survival rate for metastatic disease cases paints a grim picture. Luckily, hope emerges in the form of novel therapeutic agents for advanced, recurrent, and metastatic BC and RCC. Next, the program navigates through the pathogenesis of these cancers. Equipped with this knowledge, healthcare providers can better understand the intricacies of disease progression. As the treatment landscape rapidly evolves, so does the complexity in selection, sequencing, and adverse event (AE) management. Thus, the webcast outlines how to […]

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

The authors determined the prognostic significance of CTC enumeration and the evolution of both CTC enumeration and the HP ratio over time in the largest longitudinal CTC study in mRCC to date. Potential biomarkers to predict and track response to immunotherapy in mRCC are provided by these insights into changes in both tumor burden and the molecular profile of tumor cells in response to various treatments.